Sichuan Huiyu Pharmaceuticals

Sichuan Huiyu Pharmaceuticals is a leading Chinese biopharmaceutical company focused on the development, manufacturing, and global commercialization of high-end oncology and cardiovascular medicines. Established in 2010 and headquartered in Neijiang, the company has successfully penetrated international markets, being one of the first Chinese firms to receive EU-GMP certification for injectable oncology products. Huiyu is currently undergoing a strategic transformation from a high-quality generics provider to an innovation-led biotech, investing heavily in advanced modalities such as antibody-drug conjugates (ADCs) and mRNA technologies. Their diverse pipeline includes both complex generics and novel biologics aimed at addressing significant unmet needs in cancer treatment. The company is publicly listed on the Shanghai Stock Exchange's STAR Market.